![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Plasma Metabolites for de Novo Lipogenesis and Pharmacodynamic
Activity of Acetyl-CoA Carboxylase Inhibitor GS-0976
|
|
|
Reported by Jules Levin
AASLD: The Liver Meeting 2017, October 20-24, 2017, Washington, DC
Jacqueline M. Tarrant,1 Mona Vimal,1 Klaus-Peter Adam,2 Deirdre Hauser,2 Haibao Wan,2 Ren Xu,1 Brian J. Kirby,1 Cara Nelson,1 Adrian S. Ray,1 Ting Wang,1
Kathryn Stiede,3 William F. Westlin,3 C. Stephen Djedjos,1 Bryan J. McColgan,1 Scott D. Patterson,1 Tuan Nguyen,1 Robert P. Myers1
1Gilead Sciences, Inc., Foster City, CA; 2Metabolon, Inc., Morrisville, NC; 3Nimbus Therapeutics, Cambridge, MA
![AASDL1](../images/111417/111417-9/AASDL1.gif)
![AASDL2](../images/111417/111417-9/AASDL2.gif)
![AASDL3](../images/111417/111417-9/AASDL3.gif)
![AASDL4](../images/111417/111417-9/AASDL4.gif)
![AASDL5](../images/111417/111417-9/AASDL5.gif)
![AASDL6](../images/111417/111417-9/AASDL6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|